CIM
NKTR icon

Contravisory Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Contravisory Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-472
Closed -$117K – 271
2020
Q3 		$117K Buy
+472
New +$148K 0.04% 180

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Contravisory Investment Management's NKTR Position: Q4 2020 in Review

Contravisory Investment Management sold out of Nektar Therapeutics (NKTR) in Q4 2020, closing a stake of 472 shares — an estimated $117K sold.

Contravisory Investment Management first reported a position in NKTR in Q3 2020 and held it in 1 quarter. The position peaked at $117K in Q3 2020. 246 funds tracked by Wall St. Rank hold NKTR as of Q4 2020.

  • Contravisory Investment Management reported no remaining Nektar Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Contravisory Investment Management sold 472 Nektar Therapeutics shares in Q4 2020, an estimated $117K.
  • Contravisory Investment Management first reported a position in Nektar Therapeutics in Q3 2020 and held it in 1 quarter.
  • Contravisory Investment Management's Nektar Therapeutics position peaked at $117K in Q3 2020.
  • 246 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2020.

Based on Contravisory Investment Management's 13F filing for Q4 2020, filed 13 Jan 2021.